Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 2/20 | 0.38 |
| ▸ | PARP1 | P09874 | 2/20 | 0.38 |
| ▸ | FABP4 | P15090 | 3/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 1/20 | 0.35 |
| ▸ | RXRG | P48443 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5769799 | 0.76 | PARP1 (0.50) | PARP1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL5770181 | 0.73 | FABP4 (0.48) | FABP4 | |
| SCHEMBL6391708 | 0.70 | JAK2 (0.43) | MEN1KMT2APARP1MAPKAPK2LMNA | |
| SCHEMBL2485381 | 0.70 | GFER (0.60) | MEN1KMT2AGFERPARP1LMNA | |
| SCHEMBL6398221 | 0.68 | JAK2 (0.43) | MEN1KMT2APARP1MAPKAPK2LMNA | |
| SCHEMBL833488 | 0.68 | TDP1 (0.45) | MEN1KMT2ACXCR5RXRARXRB | |
| SCHEMBL15069471 | 0.67 | GFER (0.52) | MEN1KMT2AGFERPARP1SMN1; SMN2 | |
| SCHEMBL7682627 | 0.66 | KMT2A (0.42) | MEN1KMT2ACXCR5RXRARXRB | |
| SCHEMBL29493191 | 0.65 | CXCR5 (0.56) | MEN1KMT2AGFERCXCR5RXRA | |
| SCHEMBL783869 | 0.65 | CXCR5 (0.56) | MEN1KMT2AGFERCXCR5RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1349836-B1 | TETRACYCLIC DERIVATIVES AS SPLA2 INHIBITORS | LILLY CO ELI (US) | 2006-06-14 | — | — | EP | disclosed |
| US-6992100-B2 | sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 2006-01-31 | — | — | US | disclosed |
| US-20040092543-A1 | Novel spla2 inhibitors | BEIGHT DOUGLAS WADE (US) | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092543-A1 | Novel spla2 inhibitors | PLA2G12A, PLAAT2, SPINT2 | MEN1 4836/4885KMT2A 3392/4885GFER 1971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.